Melanoma Molecular Maps Projects


Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;

  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);

  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.

Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.

The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.


"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations.
Gugger A, Barnhill RL, Seifert B, Dehler S, Moch H, Lugassy C, Marques-Maggio E, Rushing EJ, Mihic-Probst D
PLoS One. 2016;11(5):e0156115.
PMID: 27213536 [PubMed - in process]

Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients.
Berger AC, Davidson RS, Poitras JK, Chabra I, Hope R, Brackeen A, Johnson CE, Maetzold DJ, Middlebrook B, Oelschlager KM, Cook RW, Monzon F, Miller AR
Curr Med Res Opin. 2016 May 23;():1-23.
PMID: 27210115 [PubMed - as supplied by publisher]

The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year.
Damude S, Hoekstra-Weebers JE, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ
Ann Surg Oncol. 2016 May 18;():.
PMID: 27194552 [PubMed - as supplied by publisher]

Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma.
Poukka M, Bykachev A, Siiskonen H, Tyynelä-Korhonen K, Auvinen P, Pasonen-Seppänen S, Sironen R
BMC Cancer. 2016 May 16;16():313.
PMID: 27184066 [PubMed - in process]

Choroidal Metastases From Cutaneous Melanoma.
Mercado CL, Toy BC, Kistler HB, Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina. 2016 May 1;47(5):497.
PMID: 27183558 [PubMed - in process]

NCBI's Disclaimer and Copyright notice